Skip to content

MATINAS BIOPHARMA HOLDINGS, INC.: 10-Q filed 2020-11-06

What MATINAS BIOPHARMA HOLDINGS, INC. reported in its quarterly report filed 2020-11-06 (fiscal Q3 2020): 37 published measures, 96 facts as tagged in accession 0001493152-20-020630.

This filing

Form
10-Q (quarterly report)
Filed
2020-11-06
Fiscal period
fiscal Q3 2020
Accession
0001493152-20-020630 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MATINAS BIOPHARMA HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-3074,806,426USD
At 2019-12-3140,240,155USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-306,601,207USD
At 2019-12-317,188,573USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-3068,205,219USD
At 2020-06-3072,824,671USD
At 2019-12-3133,051,582USD
At 2019-09-3037,980,746USD
At 2019-06-3040,418,090USD
At 2018-12-3116,141,724USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-307,051,225USD
At 2019-12-3122,170,438USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-5,449,513USD92
2020-01-01 to 2020-09-30-16,105,958USD274
2019-07-01 to 2019-09-30-4,404,385USD92
2019-01-01 to 2019-09-30-11,799,820USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-13,060,126USD274
2019-01-01 to 2019-09-30-9,193,089USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-01-01 to 2020-09-305,749USD274
2019-01-01 to 2019-09-30405,604USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2020-07-01 to 2020-09-3095,833USD92
2020-01-01 to 2020-09-3095,833USD274
2019-01-01 to 2019-09-3089,812USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-3047,497,264USD274
2019-01-01 to 2019-09-3029,841,637USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-49,756,351USD274
2019-01-01 to 2019-09-30-405,604USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-101,166,313USD
At 2019-12-31-84,377,555USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-09-301,581,762USD
At 2019-12-311,749,259USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-09-303,344,577USD274
2019-01-01 to 2019-09-302,297,483USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-5,604,606USD92
2020-01-01 to 2020-09-30-17,717,667USD274
2019-07-01 to 2019-09-30-4,561,257USD92
2019-01-01 to 2019-09-30-13,185,053USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-3065,203,014USD
At 2019-12-3129,922,856USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-302,838,320USD
At 2019-12-313,097,234USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-09-30373,066USD
At 2019-12-31679,310USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2020-09-301,336,488USD
At 2019-12-311,336,488USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-07-01 to 2020-09-303,336,225USD92
2020-01-01 to 2020-09-3010,833,345USD274
2019-07-01 to 2019-09-302,671,365USD92
2019-01-01 to 2019-09-307,814,842USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-30198,969,758shares
At 2019-12-31163,156,984shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2020-09-307,437USD
At 2019-12-3122,756USD
At 2019-09-3033,251USD
At 2018-12-3113,008USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-09-30165,024,057USD
At 2019-12-31113,427,897USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-09-30363,545USD
At 2019-12-31-880USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-09-303,401,136USD
At 2019-12-313,761,207USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-09-302,321USD
At 2019-12-312,315USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-09-30739USD
At 2019-12-31566USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2020-09-302,015,102USD
At 2019-12-311,939,510USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-09-302,246,128USD
At 2019-12-311,897,784USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2020-09-30341,265USD
At 2019-12-31341,265USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-01-01 to 2020-09-3016,100,000USD274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-5,563,672USD92
2020-01-01 to 2020-09-30-15,741,533USD274
2019-07-01 to 2019-09-30-4,404,385USD92
2019-01-01 to 2019-09-30-11,799,820USD273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-5,677,113USD92
2020-01-01 to 2020-09-30-16,681,350USD274
2019-07-01 to 2019-09-30-4,564,926USD92
2019-01-01 to 2019-09-30-12,487,933USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-302,364,214USD92
2020-01-01 to 2020-09-306,980,155USD274
2019-07-01 to 2019-09-301,889,892USD92
2019-01-01 to 2019-09-305,460,023USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-07-01 to 2020-09-3057,800USD92
2020-01-01 to 2020-09-30173,200USD274
2019-07-01 to 2019-09-3052,000USD92
2019-01-01 to 2019-09-30148,900USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2020-01-01 to 2020-09-30173,246USD274
2019-01-01 to 2019-09-30148,918USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-07-01 to 2020-09-30155,093USD92
2020-01-01 to 2020-09-30538,420USD274
2019-07-01 to 2019-09-30156,872USD92
2019-01-01 to 2019-09-30378,151USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-306,244USD274
2019-01-01 to 2019-09-30390,148USD273

Inspect the source

Entity
MATINAS BIOPHARMA HOLDINGS, INC. / CIK 0001582554
Captured
SEC response SHA-256
218993fbdcae524fc0c120e888a258d2be15df63a5b4cfc0f198760659dede1e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001582554.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))